Catalyst Event
Teva Pharmaceutical Industries Ltd (TEVA) · Earnings Release
From KEDI Global Longevity Bio Index (KGLB)
4/29/2026, 12:00:00 AM
Teva announced Q1 2026 financial results on 2026-04-29, reporting revenue of $4.0 billion and non-GAAP EPS of $0.53, exceeding analyst expectations. The stock rose over 7% in pre-market trading following the announcement.
Korean Translation
2026년 4월 29일 1분기 재무 실적 발표, 매출 40억 달러 및 비일반회계기준(Non-GAAP) 주당순이익(EPS) 0.53달러로 시장 예상치를 상회함. 발표 후 개장 전 거래에서 주가 7% 이상 상승함.
Related Recent Events
Biogen Inc (BIIB) · Other
FDA PDUFA target action date for LEQEMBI's subcutaneous autoinjector formulation (IQLIK SC-AI) for initiation dosing, a potential new administration option for the Alzheimer's disease treatment, scheduled for 2026-05-24. High impact expected due to the significant market potential of the Alzheimer's treatment.
5/24/2026, 12:00:00 AM
Thermo Fisher Scientific Inc (TMO) · Other
An Investor Day is scheduled for May 20, 2026, where senior management will provide presentations scheduled.
5/20/2026, 12:00:00 AM
Takeda Pharmaceutical Co Ltd (TAK) · Earnings Release
Takeda is scheduled to announce its financial results for the full fiscal year 2025 (ending March 31, 2026) on May 13, 2026. High importance is estimated as earnings reports for major pharmaceutical firms often trigger price movements exceeding 10% based on guidance. This event is scheduled.
5/13/2026, 12:00:00 AM
Natera Inc (NTRA) · Earnings Release
Q1 2026 earnings release is scheduled. Earnings announcements typically result in >5% price impact, scheduled.
5/7/2026, 12:00:00 AM
Viatris Inc (VTRS) · Earnings Release
Viatris is scheduled to report its first quarter 2026 financial results on May 7, 2026, with an estimated price impact of over 5% based on historical earnings volatility scheduled.
5/7/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
Novo Nordisk is scheduled to announce its first quarter 2026 financial results. Low importance as it is a routine earnings call, scheduled.
5/6/2026, 12:00:00 AM